EVALUATION OF PALIVIZUMAB AS PROPHYLAXIS AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION

Fernández-Fraga, F¹; López-Méndez, P¹; López-García, A¹; Ibáñez-Heras, N¹; Molina-García T¹
¹Hospital Pharmacist. Pharmacy Department. Hospital Universitario de Getafe (Madrid). Spain

BACKGROUND

RSV infection can lead to:
- Morbidity and mortality in children
- Hospitalization
- Admission to the intensive care unit

Palivizumab has been found to be effectiveness in reducing these complications in high risk infants

OBJECTIVES

To determine the effectiveness of prophylaxis with palivizumab administration on:
- Hospitalization rates for RSV
- Respiratory tract infections without RSV

MATERIALS and METHODS

- Retrospective and descriptive study from October 2012 to February 2019
- Patients with palivizumab administration were included

DATA COLLECTED

- Administrations of palivizumab per patient
- Administration dates
- Admitted patients for respiratory infection
- Date of admissions per patient
- Positive cultures in samples for RSV in admitted patients
- The need for oxygen therapy

RESULTS

N=125 patients; Average age= 2.84 months; Mean administrations: 5

- No admitted patients: 80.8%
- 1 admission: 19.2%
- >1 admission: 70.83%
- 29.17%
- 19.2%

Median time from last administration to culture VRS + ➔ 290 days (IQR 276-300)
83.33% of admitted patients ➔ needed oxygen therapy ➔ 25% required oxygen at high flow

CONCLUSIONS

- Admissions for respiratory infections were low in children with palivizumab administration.
- Small percentage of these admissions had positive cultures for VRS
- Most of patients admitted for respiratory causes needed oxygen therapy.

Conflict of interest: nothing to disclose

Email: fer.fernandez.fraga@gmail.com